Data on TMPRSS2-ERG and AR-V7 may pave the way for personalised therapy for prostate cancer (PCa) patients. Comprehensive molecular profiling can help identify multiple PCa subtypes and driving alterations. Translating these findings into clinical practice is still challenging.
Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies / Santoni, Matteo; Scarpelli, Marina; Mazzucchelli, Roberta; Lopez Beltran, Antonio; Cheng, Liang; Epstein, Jonathan I.; Cascinu, Stefano; Briganti, Alberto; Catto, James W.; Montorsi, Francesco; Montironi, Rodolfo. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - STAMPA. - 69:2(2016), pp. 186-190. [10.1016/j.eururo.2015.05.041]
Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies
SANTONI, MATTEO;SCARPELLI, Marina;MAZZUCCHELLI, Roberta;MONTIRONI, RODOLFO
2016-01-01
Abstract
Data on TMPRSS2-ERG and AR-V7 may pave the way for personalised therapy for prostate cancer (PCa) patients. Comprehensive molecular profiling can help identify multiple PCa subtypes and driving alterations. Translating these findings into clinical practice is still challenging.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
